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Abstract 
 
 
This study examines whether nonfinancial patent information is useful to 
investors in assessing and valuing biotech firm’s long-term financial performance.  The 
biotech industry requires large R&D investments with uncertain payoffs.  Current 
accounting practice expenses (rather than capitalizes) R&D expenditures.  As a result, 
financial variables are often negative or excessively depressed.  Because accounting 
assets do not reflect biotech firms’ valuable intangible assets, this study examines 
whether nonfinancial patent information supplement the information content of financial 
information in market valuation.  Using six patent variables measuring both quantity and 
quality aspects of patents, I found evidence consistent with the idea that nonfinancial 
patent information captures the biotech firms’ value not currently formally valued by 
traditional financial indicators.  In addition, patent information is associated with and can 
be useful in predicting a biotech firm’s long-term financial performance with a two-year 
lag. 
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1. Introduction 
This study examines whether nonfinancial information, particularly patent 
information, is useful to investors in assessing and valuing biotechnology firms’ long-
term financial performance.  The biotech industry is characterized by short-cycle 
technological developments requiring large investments with very uncertain payoffs.  
This high uncertainty, along with the lack of financial information disclosed, makes 
valuing biotech companies difficult.   
Current accounting practice fails to make valuing fast-changing technology-based 
industries, such as telecommunications, software production, and biotechnology, any 
easier.1  These firms make significant value enhancing investments in intangible assets, 
such as research and development, that they immediately expense for financial statement 
purposes.  As a result, financial variables, such as earnings and book values, are often 
negative or excessively depressed and appear to be unrelated to market values.  Because 
accounting assets do not reflect technology-based firms’ valuable intangible assets, this 
study investigates what nonfinancial measures investors use to supplement the 
information content of financial information in market valuation. 
To address this question, the study focuses on the biotech industry and examines 
whether a biotech firm’s stock market value reflects the intangible assets associated with 
patents.  R&D productivity (i.e., the quality and quantity of inventive output) is a vital 
determinant of long-term success in high-tech companies, particularly for the biotech 
                                                 
1 For example, Amir & Lev (1996, p. 28) state in their conclusion: “The evidence presented in this study 
indicates that current financial reporting of wireless communications companies—a large world-wide and 
technologically leading industry—is inadequate.  Specifically, significant value-enhancing investments in 
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industry because, as a percentage of revenues, R&D spending in the biotech industry is 
among the highest of any U.S. industry group.2  Economic literature usually considers 
patent information as an indicator of inventive output, which measures the productivity of 
R&D spending (i.e., an indicator of inventive input) (Hall, Jaffe, and Trajtenberg 2000; 
Harhoff, Narin, Scherer, and Vopel 1999; Griliches 1990).  A patent protects a new 
process or product from competition and allows a firm to recoup R&D costs while 
earning a good return on its investment.  Because patents are among the most important 
benchmarks of progress in developing new biotechnology products, this study uses 
publicly available patent information to determine whether market participants use this 
nonfinancial information in assessing future cash flows. 
This study should be of interest to both investors and policymakers.  From the 
investor’s perspective, the examined nonfinancial patent information provides a useful 
tool to assess biotech firms’ potential profits and future cash flows.  From the public 
policymaker’s perspective, it sheds light on the nonfinancial disclosure issue.  Although 
greater disclosure is generally believed to be preferable, accounting authorities are 
concerned that the risk of such disclosure may outweigh the benefits.  For example, 
inaccurate measurements or surprise writedowns of intangible assets may result in federal 
securities lawsuits.3  By demonstrating the value-relevance of a set of objective and 
publicly available patent measures in the biotech industry, this study contributes to the 
                                                                                                                                                 
the cellular franchise and in expanding the customer-base are fully expensed in financial reports, leading to 
distorted values of earnings and assets.” 
2 According to Ernst & Young, R&D expenditures by public biotech firms reached $9.9 billion in 2000, up 
from $6.9 billion in 1999 and $6.7 billion in 1998.  Standard & Poor’s estimates that R&D spending was 
approximately $12 billion in 2001. 
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3 According to Halsey Bullen, senior project manager at FASB (Business Week, Auguest 26, 2002, p. 110). 
discussion of what information biotech firms should disclose to improve current financial 
reporting. 
A number of studies express concerns about the declining importance of financial 
reporting and disclosure and suggest that nonfinancial value drivers may enhance 
financial statement users’ ability to evaluate and predict financial performance (Ittner and 
Larcker 1998; Behn and Riley 1999; Trueman, Wong, and Zhang 2001).  Contrary to this 
view, Francis and Schipper’s (1999) study yields no systematic evidence that indicates 
declining relevance of financial statements over years 1951-1993.  The current study 
contributes to the debate by investigating the value relevance of financial information in 
market valuation and the usefulness of nonfinancial information in predicting biotech 
firms’ financial performance.   
Deng, Lev, and Narin (1999) and Hirschey, Richardson, and Scholz (1998) 
address the relation between nonfinancial patent measures and financial performance in 
the high-tech sectors.  This study builds on their study and extends prior research by 
incorporating a richer set of patent measures, and it tests the incremental value relevance 
of nonfinancial patent information for biotech companies.  In addition, using the same 
nonfinancial patent information, this study develops a model to determine whether these 
nonfinancial variables can be used to predict future financial performance.  Unlike prior 
research, this study focuses on the biotech industry instead of the high-tech sectors in 
general.  High-tech sectors are characterized by high R&D spending and intensive R&D 
activities.  However, not all R&D intensive sectors patent significantly.  For example, the 
level of patenting is relatively low despite the high level of R&D (software development 
costs) in the software industry.  Testing whether patent information can be an appropriate 
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indicator of inventive output in the biotech industry rather than high-tech industries in 
general, therefore, yields more direct and reliable evidence.  Given the current debate 
over what information should be disclosed and audited, this study contributes to the 
existing literature by examining whether the disclosure of biotech companies could be 
improved by using all the value drivers in the business, including financial results and 
value-enhancing nonfinancial patent measures.   
This paper proceeds as follows: Section 2 provides a review of prior research on 
value relevance studies and patent measures.  Section 3 includes an overview of the 
biotechnology industry.  Section 4 provides theory development.  Section 5 develops the 
hypotheses and patent variable definitions.  Section 6 discusses the research design and 
econometrics issues.  Section 7 outlines data sources and sample selection procedures.  
Section 8 presents research findings.  Section 9 provides sensitivity tests.  Finally, section 
10 sets forth summary and concluding remarks. 
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2. Prior Research 
2.1 Nonfinancial Information and Value Relevance Studies 
According to Barth, Beaver, and Landsman (2001), “an accounting amount is 
defined as value relevant if it has a predicted association with equity market values.”  The 
extant value relevance studies use various valuation models to structure tests, and 
typically use equity market value as the valuation benchmark to assess how well 
particular accounting amounts reflect information used by investors.   The primary 
purpose for conducting tests of value relevance is to extend our knowledge regarding the 
relevance and reliability of accounting amounts as reflected in equity values. 
The emphasis on nonfinancial measures is motivated by the perceived absence of 
information on key drivers of firm value.  The Jenkins Committee report (1994) 
stimulated a number of recent studies that examine the value relevance of nonfinancial 
information.  Examples include market size and market penetration in the wireless 
industry (Amir and Lev 1996), patents in high-tech firms (Deng, Lev, and Narin 1999), 
customer satisfaction (Ittner and Larcker 1998), and Web traffic measures in the Internet 
industry (Trueman, Wong, and Zhang 2001).4  The current study extends this line of 
research by turning attention to innovative, science-based biotech companies.  The aim is 
to examine whether commonly available nonfinancial patent information can be used to 
supplement the information content of financial information and improve the disclosure 
quality and to determine how reliable these patent measures are in predicting long-term 
performance. 
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4 Appendix 1 briefly reviews models in previous nonfinancial value relevance studies.   
Most value relevance studies make inferences based on the implicit assumption 
that the stock market is efficient in the semi-strong form.  In recent years, this assumption 
has raised substantial concerns among several researchers (Lee 1999; Holthausen and 
Watts 2001; Rajgopal, Shevlin, and Venkatachalam 2001).  For example, Rajgopal, 
Shevlin, and Venkatachalam (2001) examine the association between order backlog and 
stock prices and conclude that the stock market possibly misprices non-GAAP value 
drivers.  They suggest that, if the market has trouble interpreting dollar denominated 
value driver such as order backlog, the market probably will fail to fully appreciate the 
implications of non-dollar denominated leading indicators such as customer satisfaction, 
Web traffic, and patents.    
Despite the concern over the market efficiency assumption and the non-dollar 
denominated nature of patents, examining the association between patent data and 
biotech firms’ stock market value is worthwhile for two reasons.  First, the (possible) 
market inefficiency is not large enough in magnitude to alter conclusions of value 
relevance studies.  This observation is not surprising given that arbitrage should mitigate 
the effects of market inefficiencies on the measurement of value relevance, especially 
those effects found in large data sets using publicly available information (Aboody, 
Hughes, and Liu 2000).  Second, the success of R&D activities is a vital determinant in 
biotech firms’ value.  Chan, Lakonishok, and Sougiannis (2000), however, find little 
difference between average stock price performance of firms engaged in R&D and firms 
with no R&D.  The evidence reflects investors’ lack of information about the nature and 
outcomes of firms’ R&D activity.  Because dollar denominated R&D spending under 
current accounting practice fails to provide value-relevant information, increased 
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disclosure in direct measures of a biotechnology firm’s inventive output, such as patents, 
may be beneficial.   
2.2 Patent Measures  
As patent data become more available in machine-readable form, patent-related 
measures, such as the number of patents and citation-weighted patents, seem to have 
become the most popular indicators of technological output and information flow.5  A 
patent, by definition, is a temporary legal monopoly granted to inventors for the 
commercial use of an invention.  When included in a market value equation, patents 
typically do not have as much explanatory power as an R&D measure.  However, they do 
appear to add explanatory power above and beyond R&D (Hall 1998).  One reason 
patents may not exhibit much correlation with dollar denominated measures such as R&D 
or market value is that they are an extremely noisy measure of the underlying economic 
value of the innovations with which they are associated (Grilliches, Pakes, and Hall 
1987).  Patents are an extremely noisy measure because the distribution of the value of 
patented innovations is known to be extremely skewed toward the low end, with a long 
and thin tail into the high-value side.  Therefore, the number of patents held by a firm 
may be a poor proxy for the value of knowledge assets.6  Some studies suggest that the 
number of citations received by a patent may be correlated with its economic value, so 
that weighting patents by the number of citations received may improve the measure 
(Harhoff, Narin, Scherer, and Vopel 1999).   
                                                 
5 The research using patent counts and citations as R&D output measures is summarized in Griliches 
(1990) and Hall, Jaffe, and Trajtenberg (2000).   
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Patent citations identify the number of times each patent has been cited in 
subsequent patents.  Harhoff, Narin, Scherer, and Vopel (1999) survey the German patent 
holders of 962 U.S. invention patents that also were filed in Germany, asking them to 
estimate at what price they would have been willing to sell the patent right in 1980, about 
three years after the date at which they filed the German patent.  The results show that the 
most highly cited patents are very valuable, “with a single U.S. citation implying on 
average more than $1 million of economic value.”  The citation indicators, therefore, are 
expected to have a high positive correlation with market value.   
Various studies have shown that patent citations capture important aspects of 
R&D value. For example, Trajtenberg (1990) reports a positive association between 
citation counts and consumer welfare measures for CAT scanners; Shane (1993) finds 
that patent counts weighted by citations (i.e., the firm’s number of registered patents 
divided by the number of times these patents cited by others) contribute to the 
explanation of differences in Tobin’s q measures (market value over replacement cost of 
assets) across semiconductor companies; and Hall, Jaffe, and Trajtenberg (2000) report 
that citation-weighted patent counts are positively associated with firms’ market values 
(after controlling for R&D capital). Darby, Liu, and Zucker (2000) use patents counts, 
citation-weighted patent counts, claim-weighted patent counts, and the number of the 
firm’s ties to star scientists as knowledge capital measures.  They find that firms with two 
standard deviations more knowledge capital are valued 10% to 50% more than firms with 
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6 Knowledge assets include rights to future benefits emanating from discovery and development activities 
(e.g., patents, know-how); brands, franchises and other customer-related assets; and unique organizational 
designs of corporations (Lev 2000). 
mean values of all variables.  Patent counts and citations thus reflect technological 
elements used by investors to value companies. 
Other potentially informative patent measures used in prior studies are claim-
weighted patents (Darby, Liu, and Zucker 2000), science linkage, and technology cycle 
time (Deng, Lev, and Narin 1999; Hirschey, Richardson, and Scholz 1998).  Patent 
claims define the scope of the patent protection and describe what the patented invention 
does that has never been done before.  Although simple patents have only a few claims, 
broader patents may cover separable inventions, each spelled out in a separate claim.  
Science linkage is measured as the average number of references cited on the front page 
of the patent, including academic journal articles and papers presented at scientific 
meetings.  Technology cycle time is defined as the median age in years of earlier U.S. 
patents referenced by a patent.  It shows how quickly a technology is evolving.  
Empirical analysis indicates that these patent-related measures are statistically associated 
with subsequent stock returns (Deng, Lev, and Narin 1999; Hirschey, Richardson, and 
Scholz 1998) and market-to-book ratios (Deng, Lev, and Narin 1999), suggesting that 
patent-related measures provide a useful tool for the investment analysis of technology 
and science-based firms.   
Among existing patent literature, two value relevance studies address the relation 
between nonfinancial patent measures and financial performance in high-tech firms.  
Hirschey, Richardson, and Scholz (1998) obtain data from CHI’s TECH-LINE database 
and investigate the value relevance of four patent variables, including the number of 
patents, current impact index, science linkage, and technology cycle time in high-tech 
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industries.7  They found that the four patent variables are individually and collectively 
important in explaining current market values.  Similarly, Deng, Lev, and Narin (1999) 
examine the relation between the same four patent variables and stock returns and 
market-to-book ratios, based on all firms with positive equity on CHI research files 
matched with COMPUSTAT database.  Their empirical analysis indicates that most of 
the examined patent attributes are statistically associated with subsequent stock returns 
and market-to-book ratios. 
This study complements and extends that of Hirschey, Richardson, and Scholz 
(1998) and Deng, Lev, and Narin (1999).  As mentioned earlier, not all high-tech 
industries patent significantly.  Software development and production companies, for 
example, rely heavily on copyright and trademarks instead of on patenting activities.   
Therefore, the evidence in prior research documenting the value relevance of patents in 
the high-tech sectors in general may not be sufficient and could just indicate that firms in 
industries that are more likely to seek and be granted patents tend to have higher 
value.  By focusing on the biotech industry, this paper examines the value relevance of 
patents on a set of firms that are equally likely (or more equally likely than those in 
different high-tech industries) to participate in patenting activities.  It also provides more 
direct and reliable evidence on the underlying issue.   
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7 The high-tech sector defined includes firms from SIC product group 28 (chemicals and allied products), 
29 (petroleum refining), 35 (industrial and commercial machinery and computer equipment), 36 (electronic 
and other electrical equipment), 37 (transportation equipment), 38 (measuring, analyzing and controlling 
instruments), and 48 (communications). 
2.3 Patents and R&D 
The annual R&D expenditures of a firm are considered to be investments that add 
to a firm’s knowledge asset.  This knowledge asset depreciates over time so that the older 
R&D investment becomes less valuable as time passes.  To supplement the information 
content, this study uses patent information as an indicator of the value of the additions to 
a biotech firm’s underlying knowledge capital and future earnings potential.  A 
maintained assumption of this study is that patents are an indicator of the output or 
“success” of R&D rather than an input of R&D.  Testing this assumption, however, is 
beyond the scope of the study.   
Hall, Griliches, and Hausman (1986) analyze the relation between patenting and 
R&D activity at the firm level by the U.S. manufacturing sector during the 1970’s.  They 
found that R&D and patents appear to be dominated by a contemporaneous relationship 
rather than leads or lags.  Pakes and Griliches (1984), using the standard fixed effects 
model, found evidence of a lag truncation effect in the distributed lag of patents on R&D.  
That is, the estimated coefficient on R&D expenditures of four years prior was 
significantly higher than the coefficients of more recent R&D.  Hausman, Hall, and 
Griliches (1984) used a different functional form and found similar results for the random 
effects but not in their conditional fixed effects version.  When conditioning the estimates 
on the total number of patents received during the entire period, the study found that no 
coefficient except for the contemporaneous R&D variable were statistically significant 
either in the Poisson or negative binomial version.  These earlier empirical results 
indicated a contemporaneous effect of R&D on patents but were inconclusive as to 
whether a significant lagged effect existed.  The implications of prior empirical results for 
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model specifications are that current year’s R&D should be included in the value 
relevance model and that the lagged relationship between patents and R&D may need to 
be reexamined.   
 12
3. The Biotechnology Industry 
In the context of current industrial practice, biotechnology commonly refers to the 
application of biological and biochemical science to large-scale production for the 
purpose of modifying human, health, food supplies, or the environment.  The biotech 
industry today comprises many different practices, some of which involve the alteration 
of genetic material.  Although people recognize its potential to cure diseases, many also 
fear that genetic research might result in the accidental creation and release of deadly new 
pathogens into the environment.  In the early 1980s, the Supreme Court recognized patent 
rights on genetically altered life forms.  This ruling means that U.S. biotech firms could 
continue to invest in costly research projects knowing that patents would protect their 
discoveries and ultimately maintain financial incentives.8 
The biotech industry consists of more than 1,300 public and private entities with 
over 170,000 employees (Ernst & Young 2001).  Biotech companies range in size from 
small start-ups to multibillion-dollar firms.  In 2001, the top 10 publicly-owned U.S. 
biotech firms had over $13 billion in revenue, much higher than the $6 billion obtained 
by the top 10 in 1996.  In the future, the disparity in revenue between the big firms and 
the emerging concerns is likely to grow primarily due to small biotech firms’ lack of 
potential blockbuster research and products in the pipelines. 
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8 Patents fall into three categories—utility, design, and plant.  Utility patents may be granted to anyone who 
invents or discovers any new and useful process, machine, article of manufacture, or compositions of 
matters, or any new useful improvement thereof.  Design patents may be granted to anyone who invents a 
new, original, and ornamental design for an article of manufacture.  Plant patents may be granted to anyone 
who invents or discovers and asexually reproduces any distinct and new variety of plant 
(http://www.uspto.gov/web/patnets/howtopat.htm).  Biotech firms mostly apply for utility and plant 
patents.   
The analysis of a biotech firm, like that of any company, includes a thorough 
study of both business strategy and financial health.  However, in contrast to companies 
in more mature industries, many biotech firms do not have commercial track records.  
The usefulness of looking at a biotech company’s financial statements depends largely on 
whether the firm has an earnings history.  Because the majority of biotech companies are 
in the developmental stages and not currently making money, traditional analytical 
techniques are of limited value.  For these companies, analysts and investors tend to focus 
on the future earnings potential of products in development and on whether the company 
has the researches to fully develop those products.  Absent any explicit market 
information on the value of a company’s research pipeline or technology, patents can 
serve as a proxy for the firm’s knowledge base and future earning potential. 
Current patents can lead to royalties if a company decides to license its 
technology to other firms.  Patents also protect companies by preventing potential 
competitors from entering certain markets.  A recent high-profile legal case involving 
Transkaryotic Therapies, Inc. and Amgen underscores the value of patents.  
Transkaryotic was trying to develop a version of Amgen’s Epogen anemia drug by a 
different manufacturing process than Amgen used.  Although it did not research the same 
areas that Epogen serves, Transkaryotic found a way to manufacture a similar product 
through different means.  In January 2001, a judge ruled that Transkaryotic’s process did 
in fact infringe upon a patent held by Amgen and enjoined the company from entering the 
lucrative market that Epogen serves (Standard & Poor’s 2002).  As the information 
content of financial statements may be limited, nonfinancial patent information may fill 
this gap by providing important signals of financial performance in the biotech industry. 
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4. Theory Development 
To examine whether nonfinancial patent information supplement the information 
content of financial information in market valuation, I follow recent theoretical work on 
valuation models developed by Ohlson (1995) who modeled the market value of the firm 
as a function of book value, earnings, and other relevant information.  Knowledge asset 
has a crucial role in biotech firms’ value creation.  Therefore, to apply the Ohlson method 
in the biotech setting, this paper includes knowledge asset as other relevant information 
along with accounting data, such as book value and earnings, in the valuation model.   
For a biotech firm, the largest and most important components of knowledge asset 
are its R&D expenditures and the discoveries made by its R&D activities.  When 
successfully combined, these intangibles produce the intellectual property and legal 
patents that can rapidly translate into annual sales, profits, and/or large equity market 
value (Hand 2001).  Because cumulative R&D expenditures and cumulative patent 
information measure the inventive input and inventive output that closely tie to a biotech 
firm’s future earning potential, they are used to proxy for the knowledge asset in the 
biotech industry.   
A biotech firm’s market value can then be modeled as a function of book value, 
earnings, cumulative R&D spending, and cumulative patent information.9  That is, a 
biotech firm’s market value at the end of year t can be written as: 
 
MVt = α0 + α1 BVt + α2 Et + β0 R&Dt + β1 R&Dt-1 +…+ βm R&Dt-m                                
+ γ0 PATENTt + γ1 PATENTt-1 +…+ γn PATENTt-n + εt , (1.1) 
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9 Appendix 2 presents an alternative approach to derive the return model. 
  
where MV is market value, BV is book value, E represents earnings, m is the number of 
years in the economic life of R&D spending, and n is the number of years in the 
economic life of patents.  Three problems arise in estimating equation (1.1), however.  
First, the appropriate economic life of R&D and patent information (i.e., m and n in 
equation (1.1)) in the biotechnology industry are unknown, and prior research on the 
lagged effects of R&D on patents are inconclusive.  Second, R&Dt, R&Dt-1,…, R&Dt-m 
and PATENTt, PATENTt-1,…, PATENTt-n tend to move together and may result in 
multicollinearity problem.  Third, when using time-series data over a given period, each 
lag included causes the loss of one data point.  To avoid these problems, this study 
chooses to use a return model.   
To derive the return model, I first assume that βs and γs follow Koyck distributed 
lag structure, for which the coefficients decline geometrically: 
 
βm = λβ m-1 = λ2β m-2 = … = λmβ 0 ,      
γn = λγ n-1 = λ2γ n-2 = … = λnγ 0 ,                           0 < λ <1, (1.2) 
 
where λ measures the rate of decay of R&D expenditures and patent information.  In this 
case, each coefficient is a certain proportion of the previous one, and the coefficients 
become successively smaller as they relate to earlier time periods.  It then follows that  
 
MVt = α0 + α1 BVt + α2 Et + β0 R&Dt + β0λ R&Dt-1 +…+ β0λm R&Dt-m                                
+ γ0 PATENTt + γ0λ PATENTt-1 +…+ γ0λn PATENTt-n + εt . (1.3) 
 
Next, lagging one period and multiplying by λ yields 
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λMVt-1 = α0λ + α1λ BVt-1 + α2λ Et-1 + β0λ R&Dt-1 +…+ β0λm R&Dt-m  
 + β0λm+1 R&Dt-m-1 + γ0λ PATENTt-1 +…+ γ0λn PATENTt-n  
 + γ0λn+1 PATENTt-n-1 + λεt-1 . (1.4) 
 
Subtracting equation (1.4) from equation (1.3) and modifying the left-hand side of the 
equation by subtracting and adding MVt-1 at the same time yields the following specified 
form: 
 
MVt - MVt-1 + MVt-1 - λMVt-1 = α0 (1 - λ) + α1 (BVt - λ BVt-1) + α2 (Et - λ Et-1)  
 + β0 R&Dt + γ0 PATENTt + (εt - λεt-1) ,     (1.5) 
 
where the prior years’ R&D expenditures and patent measures (i.e., R&Dt-1,…, R&Dt-m,  
PATENTt-1,…, and PATENTt-n) are cancelled out and the lagged effects of R&D on 
patent information are eliminated.  The terms R&Dt-m-1 and PATENTt-n-1 are omitted in 
equation (1.5) because, as time passes, the knowledge asset depreciates, and the older 
R&D investments and patents become less valuable (i.e., the coefficients β0λm+1 and 
γ0λn+1 approach zero).  Replacing (BVt - λ BVt-1) by (BVt - BVt-1 + BVt-1- λ BVt-1) and 
(Et - λ Et-1) by   (Et - Et-1 + Et-1- λ Et-1), equation (1.5) can be modified as: 
   
MVt - MVt-1 + MVt-1 - λMVt-1 = α0 (1 - λ) + α1 (BVt + BVt-1 - BVt-1- λ BVt-1)  
 + α2 (Et + Et-1 - Et-1- λ Et-1) + β0 R&Dt  
 + γ0 PATENTt + (εt - λεt-1) ,     (1.6) 
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Moving the terms MVt-1 - λMVt-1 in equation (1.6) from the left to the right-hand 
side and dividing both sides by MVt-1 yields the return model: 
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Finally, equation (1.7) can be written as:  
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where ∆MVt, ∆BVt, and ∆Et represent the change in market value, book value, and 
earnings from year t-1 to year t, respectively.    
Compared with equation (1.1), the return model in equation (2) does not require 
use of the economic life of R&D and patent information nor the lagged effects of R&D 
on patents.  In addition, the return model provides evidence regarding the timeliness of 
investors’ use of financial and nonfinancial patent information (Easton 1999).  Therefore, 
this study will use the return model in equation (2) as a baseline model.   
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One concern about equation (2) is that the error term is proportional to 
 MV
1
1-t
 
and may result in heteroskedasticity.  Therefore, this study uses two-way random or fixed 
effects models instead of OLS to estimate coefficients in the return model.  Two-way 
random or fixed effects models are designed to handle various types of 
heteroskedasticity.  They are more general approaches than a more structural GLS 
approach, which would ignore other unknown sources or forms of heteroskedasticity.    
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5. Hypotheses and Patent Variable Definitions 
5.1. Hypotheses 
The first part of this study examines the value-relevance of reported financial 
information and that of nonfinancial intangible knowledge capital for asset valuation in 
the biotech industry.  Biotech firms compete with others in an R&D intensive and 
technologically innovative environment.  Consequently, frequent breakthrough 
innovations based on the firms’ knowledge capital result in significant increases in the 
firms’ asset values.  A patent grants the property right to the inventor to exclude others 
from making, using, offering for sale, or selling the invention.  Thus, I predict that patent 
information captures the biotech firms’ value not currently valued by traditional financial 
indicators.  This reasoning leads to the first hypothesis, stated in the alternative form as 
follows: 
 
H1: Nonfinancial patent information adds incremental value relevance to the 
market valuation in biotech companies. 
 
 
Another important purpose of this study is to provide understanding of the role 
nonfinancial performance measures play as leading indicators of financial performance.  
Advocates argue that nonfinancial indicators of investments in intangible assets may be 
better predictors of future financial performance than are historical accounting measures.  
Itter and Larcker (1998), for example, examine the relation between customer satisfaction 
and financial performance and conclude that nonfinancial indicators should supplement 
financial measures in internal accounting systems and executive compensation plans.  In 
addition, Behn and Riley (1999) provide empirical evidence that timely nonfinancial 
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information can be useful in predicting financial performance in the U.S. airline industry, 
and they suggest that nonfinancial information disclosure may enhance traditional 
financial reporting.  This previous research leads to the second hypothesis, stated in the 
alternative form as follows:   
 
H2: Nonfinancial patent information is associated with and can be useful in 
predicting financial performance in the U.S. biotech industry. 
 
5.2. Patent Variable Definitions 
Financial statements do not report patent information under current U.S. 
accounting standards.  Testing the hypotheses requires identifying a set of patent 
variables.  In this study, I develop six patent variables based on data obtained from the U. 
S. Patent and Trademark Office.  PATNUM indicates the total number of U.S. patents 
granted to the company during a given year.  CLAIM indicates the average number of 
claims in a firm’s granted patents in a given year.  Patent claims define the scope of the 
patent protection and describe what the patented invention does that has never been done 
before.  CITATION, a citation intensity indicator, provides the average number of 
citations to the company’s patents issued in a given year, divided by the average number 
of citations to all patents in the sample granted in the same years.10  The percentage, 
rather than citation counts, is used to construct CITATION to avoid age bias caused by 
patents issued in earlier years receiving more citations than newly-granted patents.  The 
fundamental idea underlying the economic analysis of patent citations is that a large 
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10 For example, if a biotech firm’s 1996 patents on average received 2 citations from later patents up to the 
end of year 2001 and all the 1996 patents of the sample firms on average received 0.5 citations from later 
patents during the same time period, then the firm’s CITATION in 1996 is 4, calculated as 2 divided by 
0.5.   
number of citations to a patent indicates that the examined patent represents an important 
invention.11  However, because CITATION is an ex post measure, the results indicating 
the value relevance of CITATION do not imply that CITATION should be or can be 
disclosed.  REFAGE is based on the average median age of the U.S. patents cited on the 
front page of a patent.  A tendency to cite mature patents indicates that the firm engages 
in old technology.  REFNUM indicates the average number of references to scientific 
journal papers and conference proceedings cited by a patent.  This variable shows how 
strongly a patent is linked to scientific research (Deng, Lev, and Narin 1999).  DNA% is 
the percentage of genetic patents in a firm’s total granted patents in a given year.  The 
percentage, rather than genetic patent counts, is used to construct the variable to avoid the 
possible high collinearity between patent counts and genetic patent counts.  A higher 
DNA% indicates that the firm is more strongly linked to genetic research.  Of the six 
patent variables, PATNUM measures a biotech firm’s patent quantity and CLAIM, 
CITATION, REFAGE, REFNUM, and DNA% assess various aspects of quality of the 
firm’s patents. 
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11 The CITATION measure in this study includes “self citations,” namely citations to a firm’s patent in 
subsequent patents of the same firm.  Such self citations may represent construction of patent thickets or 
other behaviors that are less value-relevant than citations from other companies.  On the other hand, a self 
citation may indicate that the company continues to build on its earlier inventions.  This interpretation 
implies that self citations are more valuable than citations from others.  A preliminary investigation in Hall, 
Jaffe, and Trajtenberg (2000) indicates that “the self-citation effect is small and positive: if the ‘self’ share 
of citations is higher, the market value is higher, other things equal.”   Because the self-citation effect is not 
considered to be significant, this study does not adjust its influence on the CITATION measure.   
6. Research Design  
6.1. Value Relevance Model 
Based on the discussion in section 4, this study uses a return model as a baseline 
model.  To test whether patent measures capture the biotech firms’ value not currently 
valued by traditional financial indicators (H1), I first examine the relation between 
financial variables and returns of biotech firms.  Motivated by the Fama and French 
(1992), the return model in equation (3) adds book-to-market ratio, market value, and 
CAPM-beta as control variables.  
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+ α8 MVjt + α9 BETAjt + εjt ,       (3)  
  
where RETURNjt is measured as the change in market value of firm j from year t-1 to 
year t divided by market value at the end of year t-1; YR and FIRM are year and firm 
dummy variables included to control for time and firm variation; MVjt-1 and MVjt are 
total market value of firm j at the end of year t-1 and year t, respectively; ∆BVjt is the 
change in book value of firm j in year t; BVjt-1 is the book value of firm j at the end of 
year t-1; ∆Ejt is the change in earnings before R&D expenditures of firm j in year t; Ejt-1 
is earnings before R&D expenditures of firm j at the end of year t-1; R&D jt is  the R&D 
expenditures of firm j at the end of year t; B/Mjt is the book-to-market ratio of firm j at 
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the end of year t; and BETAjt is the CAPM-beta of firm j, estimated from 60 monthly 
stock returns (minimum of 24) to the end of year t.   
To test the incremental value relevance of patent information, I then regress 
returns on financial information along with six patent variables using the following 
model: 
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where 
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 PATNUM
 is the total number of U.S. patents granted to firm j in a given year t, 
deflated by the firm’s market value at the end of year t-1; 
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 1-jt
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MV
 DNA%*PATNUM
 are interaction terms of deflated PATNUM and each of the five 
patent quality variables (e.g., 
 1-jt
jt
MV
 CLAIM*PATNUM
 is the interaction of 
 1-jt
jt
MV
 PATNUM
 
and CLAIMjt).  The five patent quality variables (defined in section 5.2) represent 
averaged patent attributes (CLAIM, REFAGE, and REFNUM) or indices (CITATION 
and DNA%) and can measure the potential of a biotech firm’s patents in turning to 
marketable and quality products.  Therefore, I expect that the change in a biotech firm’s 
returns corresponding to a unit change in deflated PATNUM depends on the various 
aspects of patent quality measured by the five patent quality variables.  In other words, 
each of the patent quality variables has an effect on a firm’s return through the firm’s 
total patents, and the interaction terms capture that impact.12  If the coefficients of patent 
variables (β7 through β12) are jointly statistically significant and the R-squares of 
regression (4) exceeds that of regression (3), one can conclude that patent information 
adds incremental value relevance to the market value of the biotech companies. 
6.2. Performance Model 
Performance model follows the same logic in value relevance model and 
empirically tests the ability of nonfinancial measures in year t to predict future annual 
financial performance in year t+n (H2).  Three performance variables are examined, 
including revenues (REV), margins (MAR), and return on sales (ROS).  Margins are 
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12 An implicit assumption of equation (4) for not including CLAIM, CITATION, REFAGE, REFNUM, and 
DNA% as independent regressors is that the direct impact of patent quality variables on returns of a biotech 
firm is zero.  Table 6 in section 9 presents the regression results releasing this restriction.  The results with 
or without this restriction are similar. 
defined as revenues minus R&D expenditures, and return on sales as margins divided by 
revenues.  I estimate the following basic model following work done by Itter and Larcker 
(1998): 
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where PATNUM, PATNUM*CLAIM, PATNUM*CITATION, PATNUM*REFAGE, 
PATNUM*REFNUM, and PATNUM*DNA% are the same set of patent variables used 
in equation (4).  In addition, 
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ROSjt+n and ROSjt are the performance variables that substitute for PERFORMjt+n and 
PERFORMjt in equations (5.1), (5.2), and (5.3), respectively.  Finally, R&Djt is the R&D 
expenditures of firm j at the end of year t and LnASSETjt+n is the log of a firm’s total 
assets in year t+n.  ROSjt+n and ROSjt are not scaled by MVjt-1 because they are ratios 
instead of dollar amounts.  LnASSET is included in the model to control for size effects.  
If coefficients γ1 to γ6 in equation (5.1), (5.2), and (5.3) appear to be jointly statistically 
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significant, one can conclude that patent information is a useful predictor of future 
financial performance. 
6.3. Econometrics Issues 
A potential problem in the above equations incorporating patent variables is the 
degree of multicollinearity, which results in a higher standard error of estimate.  I apply 
tests to examine the degree of multicollinearity, including using an F-test for the full 
model and checking variance inflation factor (VIF).  Multicollinearity is not an issue in 
testing the hypotheses if the patent variables in the equation are jointly statistically 
significant.  However, if the patent variables are not jointly statistically significant and 
the multicollinearity among them appears to be high, a patent index will be created to 
alleviate this problem.   
Another concern is that the above models might contain omitted variables.    
Factors not incorporated in this study, such as human capital, strategic alliances with 
major pharmaceutical firms, FDA approvals, and technology platform, also could drive a 
biotech firm’s value.  These potential value drivers are not incorporated in this study 
because they either are difficult to quantify or do not apply to the entire biotech sample, 
e.g., the number of FDA approvals is not a valid value drivers to a pure biotech firm 
without commercialized products or drugs in the pipeline.  The omitted variable bias will 
be large if omitted variables are important in the model or if they are related statistically 
to included variables.   Examples for variables that are related statistically to patent 
variables but are not included in this study are human capital and research resources 
available in the neighborhood (i.e., number of research institutes or universities).  A 
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biotech firm employing more scientists with continuous distinguishing publication 
records and having more national labs in the neighborhood may be more likely to succeed 
in creating quality patents.  Due to the potential omitted variable bias, the interpretation 
and application of the findings should be with caution. 
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7. Data Sources and Sample Selection 
7.1 Data Sources 
Nonfinancial patent data on five patent attributes (PATNUM, CLAIM, 
CITATION, REFAGE, and REFNUM) for the years 1990-2001 are from the United 
States Patent and Trademark Office’s (PTO) Web page.  If a patent found on PTO 
matches with one on the DNA Patent Database (DPD), the patent is identified as a DNA 
patent.  DPD is a joint project of the Georgetown University’s Kennedy Institute of 
Ethics and the Foundation for Genetic Medicine.  The DPD is being created to enable 
relevant empirical studies of DNA-based patents issued in the United States.  Patents 
included in the DPD were identified by virtue of their USPTO classification numbers and 
the presence of keywords such as “DNA,” “nucleotide,” or “polynucleotide” in one or 
more claims.  All financial data are obtained from the Compustat database. 
7.2 Sample Selection 
Financial analysts and investors have various definitions for the biotech industry.  
This study adopts Standard & Poor’s Market Insight industry classification, which 
defines the biotechnology industry as companies primarily involved in the development, 
manufacturing, or marketing of products based on advanced biotechnology research.  
Preliminary investigation reveals an initial sample contains 292 U.S. biotechnology 
companies on Market Insight that generate $27,090 million in combined annual sales 
(based on 12-month moving data).  The analysis is based on these companies’ financial 
and nonfinancial data for the years 1990-2001.  A search of Compustat results in 255 
possible sample companies with 1,551 firm-year observations available.  Of those 1,551 
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firm-year observations, 273 are lost when constructing 1-year lagged data, and 95 firm-
year observations are deleted because of negative book values.13  Firms with negative 
book values are eliminated from the analysis because, pratically, those firms are bankrupt 
and the normal assumption of the earnings-returns or patent-returns relation may not 
hold.  The final sample consists of 231 companies with 1,183 firm-year observations. 
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13 An inclusion of the 95 firm-year observations with negative book values yields similar results. 
8. Results 
Table 1 provides descriptive statistics for the full sample.14  Descriptive statistics 
for undeflated variables are in Panel A.  The mean PATNUM is 4.69, but the large 
standard deviation (12.85) and the relatively low median (2) indicate high variability of 
patent counts across firms and the presence in the sample of a few firms with a large 
number of patents.  Similar variability and skewness can be observed in other patent 
variables.  The mean CITATION, 0.71, indicates that averagely sample biotech firms 
have lower-than-average citations.  The median CITATION, 0.21, indicates that half of 
the biotech firms received 21% or less of the average citations in the industry.  On 
average, sample biotech companies make 13.2 claims and cite 16.3 scientific study or 
conference proceedings per patent application.  The patents cited by the firms have a 
median age of 4.43 years (mean REFAGE = 4.43).  The percentage of genetic patents in 
total granted patents in a year for the sample biotech firms on average is 26% (mean 
DNA% = 0.26).  The size of sample firms ranges from $0.34 million to $87,878.6 million 
in market value.  Because of low sales revenue and high R&D expenditures, MAR and 
ROS are negative for more than half the 1,183 firm-year observations (median MAR = -
2.33; median ROS = -0.46).  Panel B of Table 1 reports descriptive statistics for deflated 
variables used in regression models.  All variables (except for 1/MVt-1) in Panel B are 
scaled by MVt-1. 
Table 2 provides a correlation table for sample variables.  The patent variables 
with the highest correlation are CLAIM and REFAGE at 52%, REFAGE and REFNUM 
at 41%, and CLAIM and REFNUM at 40%.  When CLAIM, REFNUM, and REFAGE 
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are included in the same model, the high correlation among them might impair the 
model’s ability to explain the variation in returns.  Therefore, in the sensitivity tests 
section when regressing returns on deflated PATNUM and patent quality variables, the 
alternative models excluding two of the three highly correlated variables at each time are 
also presented for comparison purpose (Columns D to F in Table 6).  The independent 
variables with the highest correlations are REV/MVt-1 and MAR/MVt-1 at 83%.  Because 
the performance variables, REV/MVt-1 and MAR/MVt-1, are each identified as an 
independent variable in different regressions (equations (5.1) and (5.2), respectively), the 
high correlations between these variables do not affect the regression results.   
Panel A of Table 3 provides descriptive statistics on undeflated variables for 
biotech firms with and without patents used in the empirical tests.  The top statistic for 
each variable is for firms with patents; parenthetically below is the comparable statistic 
for those without patents.  T-tests are used to examine whether significant univariate 
differences exist.  Except for MVt-1 and BETA, the mean values of the variables for firms 
with patents are significantly different than those for firms without patents at 
conventional levels.  Compared with the without-patent group, the with-patent group has 
larger numbers in MV, LnASSET, and RND.  Apparently, large biotech firms with 
intensive R&D investment are more likely to be successful in knowledge assets 
development.  The statistics of performance variables reflect the importance of 
knowledge assets in the biotech industry, given that, on average, firms with patents have 
better performance than those without patents in terms of revenues, margins, and return 
on sales.  The with-patent group also has higher mean and median values in RETURN, 
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14 All tables are located in Appendix 3. 
which implies that patents add to biotech firms’ future earning potential and that 
investors value patents in market valuation.  Panel B of Table 3 reports the SIC 
composition of the sample.  Approximately 81% of the sample observations are in the 
drugs and pharmaceuticals segment (SIC codes beginning with 283), and, on average, 
69% of those in drugs and pharmaceuticals segment have patents.  Similarly, about 68% 
of overall sample observations are in the with-patent group, suggesting a general 
tendency of biotech firms to engage in patenting activities. 
Table 4 presents results of regressing returns on financial, patent, and control 
variables, using two-way random or fixed effects models.  The results of fixed effects 
models are omitted because the low H values (reported in the Hausman test) favors 
random effects models.  The R2 in the regression incorporating all financial, patent, and 
control variables is six percentage points higher than that in the regression with only 
financial and control variables (R2 = 0.29 vs. 0.26).  The F-statistic to test the incremental 
value relevance of patent information is 9.08, rejecting the null hypothesis that the 
coefficients of all six patent variables are jointly zero (in the full model containing all 
financial, patent, and control variables) at the 1% significance level.  These results 
indicate that patent information adds incremental value relevance to the market valuation 
of the biotech companies.   
The negative coefficient estimate of deflated PATNUM in column C of Table 4 
indicates that a patent with zeros in all patent attributes reduces a biotech firm’s return.  
However, a biotech firm’s patent with average patent attributes contributes to 0.18 
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percentage point increase in its return, 15  consistent with the positive coefficient of 
deflated PATNUM shown in column B.  The results in the full model may be 
questionable due to the multicollinearity among the PATNUM and PATNUM interaction 
variables.16  The multicollinearity leads to the regression of returns on financial, control, 
and each single PATNUM interaction variables.   As shown in columns D to H, each 
interaction variable is significant at the conventional level, indicating that the change in a 
biotech firm’s returns corresponding to a unit change in deflated PATNUM depends on 
the level of patent quality.   
Table 5 reports the OLS results of equations (5.1), (5.2), and (5.3).  Panel A and B 
present the results of using patent variables to predict performance for one and two years 
subsequent to the year examined, respectively.17  Panel A indicates that current year’s 
performance, including revenues, margins, and return on sales, is useful in predicting 
next year’s performance (significant at the 1% level).  Patent variables are jointly 
significantly associated with one-year subsequent return of sales (F-statistic = 11.17), but 
not for revenues and margins.  However, with a two-year lag, patent information is 
jointly significantly associated with and can be useful in predicting a biotech firm’s 
revenues, margins, and return on sales.  Panel B reports the results.   
 
                                                 
15 It is calculated as sum of the multiplicative results of the mean and coefficient estimate of each patent 
variable.  That is, 0.05*(-8.45) + 0.9*0.33 + 0.03*5.07 + 0.31*0.38 + 1.06*(-0.01) + 0.02*1.66 ≈ 0.18. 
16 The VIFs for PATNUM, PAT*CLAIM, PAT*CITATION, PAT*REFAGE, PAT*REFNUM, and 
PAT*DNA% (all deflated by MVt-1) are 24.52, 5.12, 2.06, 8.30, 5.42, and 9.55.  The high VIFs of 
PATNUM and PAT*DNA% imply the existence of collinearity.  The estimated coefficients of PATNUM 
and DNA% may be unreliable. 
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17 The results of predicting three, four, and five years subsequent performance are insignificant and thus not 
tabulated.  Because the sample covers 12-year data and most sample firms are younger than 12 years, this 
study did not examine the predictive power of patent information beyond five years.  
Interestingly, in panel B, the coefficient of the deflated PATNUM and DNA% 
interaction is positive in the revenue regression but negative in the margins and return on 
sales regressions at the conventional significance level.  In other words, an increase in the 
percentage of genetic patents to the total number of patents improves the change in a 
biotech firm’s two-year ahead sales revenues but deteriorates the change in margins and 
returns on sales, corresponding to a unit change in current year’s deflated PATNUM.  
The results suggest that, due to the potential of genetic patents in developing new 
marketable and profitable medical products, a biotech firm with a high percentage of 
genetic patents in its patent composition could contribute positively to 2-year ahead 
revenues.  However, the subsequent R&D expenditures of turning those genetic patents 
into quality and profitable products also may grow, even at a higher rate than revenues 
do, hereby resulting in the negative coefficient of the deflated PATNUM and DNA% 
interaction in the margins and return of sales regressions. 
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9. Sensitivity Tests 
The first sensitivity test examines the effect of including all five patent quality 
variables along with deflated PATNUM and its interaction terms in testing the 
incremental value relevance of patent information, that is, to estimate an unrestricted 
version of equation (4).   
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 + β16 
 1-jt
jt
MV
 REFNUM*PATNUM
  
 + β17 
 1-jt
jt
MV
 DNA%*PATNUM
 + β18 B/Mjt + β19 MVjt + β20 BETAjt + εjt  .   (4’) 
 
In equation (4’) each patent quality variable may influence returns directly (in 
coefficients β8 to β12) or indirectly through the interaction with PATNUM (in coefficients 
β13 to β17).  Table 6 summarizes the results of this alternative model specification.  As 
shown in column C, the R2 of the full model is seven percentage points higher than that 
of the regression with only financial and control variables (column A).  The F-statistic of 
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6.41 rejects the null hypothesis that the coefficients of all patent variables (β7 through 
β17) are jointly zero in the full model at the 1% significance level.  On average, a biotech 
firm’s patents and patent attributes contribute to a 0.08 percentage point increase in its 
return.  These results support the incremental explanatory power of patent information 
and agree with the return model presented in Table 4.  In addition, to test whether each 
patent variable is individually significantly associated with returns in the full model, I use 
the F test to determine whether the coefficients of all regressors involving the underlying 
patent variable are jointly zero.  (For example, CLAIM is value relevant if the null 
hypothesis that both β8 and β13 equal to zero is rejected).  Results reveal that PATNUM, 
CLAIM, CITATION, REFAGE, and DNA% each has influence on a biotech firm’s 
returns in the full model, even though the t ratios for the coefficients of CITATION and 
REFAGE are less than 2.0.18   
Column B of Table 6 presents the results of equation (4’) without presence of 
interaction terms.  The results again support the incremental value relevance of patent 
information.  Particularly, the t test shows that PATNUM and DNA% are significantly 
positively associated with returns in this model specification.  Because of the high 
correlations among REFNUM, REFAGE, and CLAIM as shown in Table 2, columns D 
to F report the regression results of excluding two of the three highly correlated variables 
at a time for comparison purposes.19  The results are comparable to those in column B. 
                                                 
18 The F-statistics are 14.11 for CLAIM (significant at the 1% level), 5.51 for CITATION (at the 1% level), 
2.53 for REFAGE (at the 10% level) and 4.24 for DNA% (at the 5% level).  
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19 The VIFs for deflated PATNUM, CLAIM, CITATION, REFAGE, REFNUM, and DNA% are 1.04, 
1.49, 1.13, 1.48, 1.37, and 1.19, respectively, suggesting that no notable multicollinearity exists in this 
model specification. 
The second sensitivity test examines whether patent information is value relevant 
in a subsample of biotech firms with losses before R&D expenditures.  Ertimur (2003) 
shows that firms reporting accounting losses experience higher levels of information 
asymmetry among investors than do those reporting profits.  In this situation, one should 
expect to see that patent information mitigates the information asymmetry and provides 
more explanatory power in firms with net losses.  Table 7 reports the regression results 
supporting this line of reasoning.  Compared with the six percentage points increase in 
the R2 in the full sample (column C in Table 4), the R2s in the regressions incorporating 
both financial and patent variables (columns B and C) are thirteen and seventeen 
percentage points higher than the R2 in the regression with only financial variables.  The 
results indicate that patent variables provide more explanatory power for firms with 
losses before R&D expenditures than for those in the full sample.  Patent information 
help mitigates the information asymmetry in biotech firms with losses before R&D 
expenditures.  In addition, a patent with average value of all attributes results in 0.26 and 
0.05 percentage point increase in a biotech firm’s return, consistent to the findings in 
Table 4.  
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10. Conclusions, Limitations, and Future Research 
In this study, I examined the association between nonfinancial patent information 
and financial information in the biotechnology industry and investigated whether this 
nonfinancial information is useful to investors in assessing biotechnology firms’ long-
term financial performance.  I found evidence consistent with the idea that patent 
information captures the biotech firms’ value not currently formally valued by traditional 
financial indicators and adds incremental value relevance to the market valuation of the 
biotech companies.  In addition, patent information is associated with and can be useful 
in predicting a biotech firm’s long-term financial performance, with a two-year lag.   
This research is important because both academics and policymakers have 
expressed concerns about the declining importance of financial reporting and disclosure 
and have suggested that nonfinancial leading indicators showing how key business 
processes are performing may enhance financial statement users’ ability to evaluate and 
predict financial performance.  Given the current debate over what information should be 
disclosed and audited, this study contributes to the existing literature by providing 
empirical evidence that the disclosure of biotech companies could be improved by using 
all the value drivers in the business, including both financial results and value-enhancing 
nonfinancial patent measures.  However, this study has its limitations. 
One of the limitations is that no theoretical functional form exists for the relation 
between patent information and financial performance.  Although this study assumes 
linearity, the relation also could be nonlinear.  Thus, one extension may be for 
researchers to build an analytical modeling foundation.  Another limitation is that this 
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research is completed at the industry level.  The focus on a specific industry adversely 
impacts the generalizability of the findings.  However, Amir and Lev (1996) argue that 
analyses gained from industry studies are often more insightful than those found in 
general cross-sectional studies.  
As mentioned earlier, human capital, strategic alliances, with major 
pharmaceutical firms, FDA approvals, and technology platform also could drive a biotech 
firm’s value.  For example, Ely, Simko, and Thomas (2003) illustrate the usefulness to 
investors of drug development information disclosed by start-up biotech firms.  Although 
further research may be warranted on potential nonfinancial value drivers, I conducted 
the analysis of patent measures and financial performance only and will leave the 
exploration of other value nonfinancial leading indicators for subsequent research.  
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Appendix 1: Valuation Models in the Value Relevance Literature 
This appendix describes the valuation models frequently used in prior value 
relevance studies, particularly those examining the association between nonfinancial 
information and equity market values.  For the most part, valuation models test the value 
relevance in terms of the level of firm value.  Examining changes in share prices, or 
returns, is an alternative approach to assessing value relevance (Ohlson 1995).  Selection 
of which approach to use depends jointly on the hypotheses dictated by the research 
question and on econometric considerations (Kothari and Zimmerman 1995).  A 
summary of the valuation models in three value relevance studies in nonfinancial 
information follows. 
Ely, Simko, and Thomas (2003) examine the incremental association of market 
value with certain summary financial variables conditioned on a nonfinancial drug 
development stage variable in the biotech industry.  The regression includes as financial 
independent variables net book value (NBV) and net income decomposed into R&D 
expenses XRD and net income before XRD (NibRD): 
 
MVEit = α0 + α∑
=
7
1j
jYRit + β1 NBVit + β2 NibRDit + β3 XRDit + δ1 AGEit  
 + ∑ δ
=
6
2k
k (Drug Phase)it + εit , 
 
where Drug Phase is the count of drugs in-process for each five possible development 
stages.  To mitigate potential scale effects each variable in the regression, including the 
intercept, is deflated by total shares outstanding. 
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Deng, Lev, and Narin (1999) examine whether patent attributes are significantly 
associated with subsequent stock returns and market-to-book ratios.  Specifically, they 
run the following pooled cross-sectional regressions: 
 
M/Bi,t+τ = α1 NPATit+ α2 CIMPit + α3 SLit+ α4 TCit + α5RNDINTit + α6 SPILit 
 + α7E/Bit + εit , 
 
Ri,t+τ = α1 NPATit+ α2 CIMPit + α3 SLit+ α4 TCit + α5RDINTit + α6 SPILit + α7Sizeit 
+ α8B/Mit + εit , 
 
where M/B is a firm’s ratio of market value to book value at one, two, and three years (τ 
= 1, 2, 3) after fiscal year-end.  NPAT is the firm’s number of patents granted in year t, 
scaled by the book value (equity) of the firm.  CIMP is Citation Impact.  SL is the 
Science Linkage indicator.  TC is the Technology Cycle Time indicator.  NPAT, CIMP, 
SL, and TC are nonfinancial patent variables.  RDINT is the R&D intensity.  SPIL is a 
spillover indicator.  Size is firm size measured as total market value.  B/M is the firm’s 
ratio of book value to market value.  RDINT, SPIL, Size, and B/M are control variables.  
E/B is the earning-to-book ratio and represents financial information. 
Jorion and Talmor (2001) examine the value relevance of financial and 
nonfinancial Web traffic information in Internet industry in the light of the theory of life-
cycle stages.  They find that, as the industry matures, gross profit and R&D become 
increasingly value relevant.  Importantly, a clear negative time trend appears in the Web 
traffic measures.  Although still of high importance, the value relevance of non-financial 
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Web traffic measures has materially diminished over the 24-month testing period.  
Assuming linear form, they investigate the value relevance using the following set-up: 
 
it
it
AV
MV
= a0 + a1 
it
it
AV
BV
+ a2
it
it
AV
F +a2’(T*
it
it
AV
F ) +a3
it
it
AV
WEB +a3’(T*
it
it
AV
WEB ) + εit , 
 
where MV is market value; BV is book value; AV is book value of assets; F denotes a 
vector of income statement variables; and WEB  represents the Internet usage (Web 
traffic). 
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Appendix 2: Alternative Approach in Deriving Return Model  
In the alternative framework, a biotech firm’s market value is separated into three 
components: market value of tangible assets, market value of intangibles related to R&D 
activities, and market value of intangibles related to patents.  That is, a biotech firm’s 
market value at the end of year t can be written as: 
 
MVt = MV(TA)t + MV(R&D)t + MV(PATENT)t ,  (A1.1) 
 
and the change of market value in year t can be expressed as: 
 
∆MVt = ∆MV(TA)t + ∆MV(R&D)t + ∆MV(PATENT)t , (A1.2) 
 
where MV(TA) is the market value of tangible assets; MV(R&D) is the market value of 
intangibles related to R&D activities; MV(PATENT) is the market value of intangibles 
related to patents; and ∆ represents the change of the variable in year t.   
The market value of R&D activities is a function of cumulative R&D 
expenditures.  Therefore,  
                 
MV(R&D)t = δ0 + β0 R&Dt + β1 R&Dt-1 +…+ βm R&Dt-m + εt , (A1.3) 
 
where m is the number of years in the economic life of R&D expenditures.  Assume that 
βs follow a Koyck distributed lag structure, for which the coefficients decline 
geometrically following the rate of decay of R&D expenditures, λR&D.  That is, assume   
 
βm = λR&Dβ m-1 = λ R&D 2β m-2 = … = λ R&D mβ 0 ,           0<λ R&D <1.  (A1.4)  
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Then equation (A1.3) becomes: 
 
MV(R&D)t = δ0 + β0 R&Dt + β0λR&D R&Dt-1 +…+ β0λR&Dm R&Dt-m + εt . (A1.5) 
 
Lagged one period and multiplied by λR&D, equation (A1.5) becomes: 
 
λR&D MV(R&D)t-1 = δ0λR&D + β0λR&D R&Dt-1 +…+ β0λR&Dm R&Dt-m  
 + β0λR&Dm+1 R&Dt-m-1 + λR&Dεt-1 . (A1.6) 
 
Next, subtracting equation (A1.6) from equation (A1.5) and modifying the left-hand side 
of the equation by subtracting and adding MV(R&D) t-1 at the same time yields the 
following specified form:  
 
MV(R&D)t - MV(R&D)t-1 + MV(R&D)t-1 - λR&DMV(R&D)t-1 = δ0 (1 - λR&D)  
 + β0 R&Dt + (εt - λR&Dεt-1) , (A1.7) 
 
where the prior years’ R&D expenditures are eliminated.  The term R&Dt-m-1 is omitted 
in equation (A1.7) because, as time passes, the knowledge asset depreciates, and the older 
R&D investments become less valuable (i.e.,  β0λR&Dm+1 approaches zero). 
Moving the terms MV(R&D)t-1 - λR&DMV(R&D)t-1 in equation (A1.7) from the 
left-hand to the right-hand side and dividing both sides by MV(R&D)t-1 yields: 
 
∆MV(R&D)t = -(1-λR&D) MV(R&D)t-1 + δ0 (1 - λR&D) + β0 R&Dt + (εt - λR&Dεt-1).  
 (A2.1) 
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Similarly, for patent-related intangible capital: 
 
∆MV(PATENT)t = -(1-λPAT) MV(PATENT)t-1 + ϕ0 (1 - λPAT) + γ0 PATENTt  
 + (ξt - λPATξt-1) , (A2.2) 
 
where λPAT is the rate of decay of patents, and  
 
γn = λPATγ n-1 = λ PAT 2γ n-2 = … = λ PAT nγ 0 ,           0< λ PAT <1. (A2.3) 
 
Now summing MV(TA)t, (A2.1), and (A2.2) gives total change in MVt: 
 
∆MVt  = ∆MV(TA)t + ∆MV(R&D)t + ∆MV(PATENT)t 
 = ∆ MV(TA)t - (1-λR&D) MV(R&D)t-1 - (1-λPAT) MV(PATENT)t-1  
 + δ0 (1 - λR&D) + ϕ0 (1 - λPAT) + β0 R&Dt + γ0 PATENTt  + (εt - λR&Dεt-1)  
 + (ξt - λPATξt-1) . (A3.1) 
 
Assume that λR&D = λPAT = λ, equation (A3.1) can be modified as: 
 
∆MVt  = ∆ MV(TA)t - (1-λ) [MV(R&D)t-1 + MV(PATENT)t-1 ] + (1 - λ) (δ0 + ϕ0)  
 + β0 R&Dt + γ0 PATENTt + (εt - λεt-1) + (ξt - λξt-1) . (A3.2) 
 
Equation (A1.1) shows that  
 
 MVt-1 = MV(TA)t-1 + MV(R&D)t-1 + MV(PATENT)t-1,   (A3.3) 
and   
 MV(R&D)t-1 + MV(PATENT)t-1 = MVt-1 - MV(TA)t-1. (A3.4) 
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Thus, equation (A3.2) can be revised using equations (A3.3) and (A3.4) as follows: 
 
∆MVt  = ∆ MV(TA)t - (1-λ) [MVt-1 - MV(TA)t-1 ] + (1 - λ) (δ0 + ϕ0) + β0 R&Dt  
 + γ0 PATENTt + (εt - λεt-1) + (ξt - λξt-1) . (A3.5) 
 
Now dividing both sides by MVt-1 gives: 
 
1-t
t
MV
MV∆
 = 
 MV
MV(TA)
1-t
t∆  + (1-λ)
 MV
 MV(TA)
1-t
1-t  - (1-λ) + (1 - λ) (δ0 + ϕ0)  MV
1
1-t
 
+ β0 
 1-t
t
MV
 D&R
 + γ0 
 1-t
t
MV
PATENT
 + 
 1-t
1 1-tt 
MV
)() -( −−+ tt λξξλεε  . (A3.6) 
 
Assuming that the market value of tangible assets is a function of book value and 
earnings, the market value of tangible assets in year t and t-1 can be expressed as: 
  
 MV(TA)t = α0 + α1 BVt + α2 Et + µ t , (A3.7) 
 MV(TA)t-1 = α0 + α1 BVt-1 + α2 Et-1 + µ t-1 . (A3.8) 
 
Subtracting equation (A3.8) from equation (A3.7) gives the change of market value in 
year t: 
 
 ∆MV(TA)t = α1 ∆BVt + α2 ∆Et + ∆µt . (A3.9) 
 
Modifying equation (A3.6) with equations (A3.8) and (A3.9) finally yields: 
 
1-t
t
MV
MV∆
 = 
 MV
EBV
1-t
tt2t1 µαα ∆+∆+∆  + (1-λ)
 MV
 EBV
1-t
1-t1-t21-t10 µααα +++  - (1-λ)  
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+ (1 - λ) (δ0 + ϕ0)  MV
1
1-t
+ β0 
 1-t
t
MV
 D&R
 + γ0 
 1-t
t
MV
PATENT
  
+ 
 1-t
1 1-tt 
MV
)() -( −−+ tt λξξλεε   
= (α0 + δ0 + ϕ0) (1 - λ)  MV
1
1-t
 + α1  MV
BV
1-t
t∆  + α2  MV
E
1-t
t∆   
+ α1 (1-λ)  MV
BV
1-t
1-t  + α2 (1-λ)  MV
E
1-t
1-t  + β0 
 1-t
t
MV
 D&R
 + γ0 
 1-t
t
MV
PATENT
  
 - (1-λ) + 
 1-t
 1-tt 1 1-tt 
MV
) -()() -( λµµλξξλεε +−+ −tt  . (A4.1) 
 
The variables included in equation (A4.1) are identical to those in the return model 
presented in equation (2) of section 4. 
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Appendix 3: Tables 
TABLE 1 DESCRIPTIVE STATISTICS 
 
Panel A: Undeflated Variables 
 
Variable Mean Std Dev Min Median Max 
Financial      
MVt-1 941.70 7007.91 0.45 115.83 152398.00
R&D 28.23 71.13 0 11.34 875.10 
      
Patent      
PATNUM 4.69 12.85 0 2 248 
CLAIM 13.20 14.60 0 11.71 176 
CITATION 0.71 1.63 0 0.21 30.61 
REFAGE 4.43 4.29 0 4.41 27.08 
REFNUM 16.30 23.39 0 8.11 230 
DNA% 0.26 0.38 0 0 1.00 
      
Performance      
REV 57.12 262.74 0.01 7.4 4015.70 
MAR 28.88 204.66 -654.64 -2.33 3150.70 
ROS -9.28 49.37 -1000.37 -0.46 1.00 
      
Control      
BM 0.37 0.46 0.00 0.25 5.80 
MV 999.48 5973.75 0.34 128.93 87878.60 
BETA 1.68 0.82 0.00 1.62 6.44 
LnAsset 3.73 1.53 -0.92 3.69 8.77 
Obs = 1183 (872 for BETA)         
 
MVt-1  = Market value of a firm at the beginning of a given year.  
R&D  = R&D expenditures. 
PATNUM = Number of U.S. patents granted to the company during a given year. 
CLAIM  = Average number of claims in a firm’s granted patents in a given year. 
CITATION = Total number of citations to the firm’s patents issued in a given year, divided by the average 
number of citations to all patents in the sample granted in the corresponding years. 
REFAGE  = Median age of the U.S. patents cited on the front page of a patent. 
REFNUM  = Number of references to scientific journal papers and conference proceedings cited by a 
patent. 
DNA% = Percentage of genetic patents in a firm’s granted patents in a given year. 
REV = Sales revenue. 
MAR = Margins, defined as sales revenue minus R&D expenses. 
ROS = Return on sales, defined as MAR divided by sales revenues. 
BM  = Book-to-market ratio. 
MV = Total market value of a firm at the end of a given year. 
BETA  = CAPM-beta of each firm. 
LnAsset = Log of a firm’s total assets. 
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TABLE 1 CONTINUED 
 
Panel B:  Deflated Variables  
All financial (except for 1/ MVt-1), patent, and performance variables are deflated by MVt-1. 
 
Variable Mean Std Dev Min Median Max 
RETURN 0.51 2.37 -0.98 -0.09 40.25 
      
Financial      
1/MVt-1 0.04 0.13 0.00 0.01 2.23 
∆BVt 0.08 0.43 -1.85 0.00 5.20 
∆Et 0.02 0.22 -2.23 0.00 4.69 
BVt-1 0.37 0.44 0.00 0.25 5.80 
Et-1 0.00 0.20 -4.10 0.00 1.09 
R&D 0.15 0.26 0 0.09 4.68 
      
Patent      
PATNUM 0.05 0.16 0 0.01 2.23 
PATNUM*CLAIM 0.89 3.37 0 0.14 69.82 
PATNUM*CITATION 0.03 0.09 0 0 1.24 
PATNUM*REFAGE 0.29 1.13 0 0.05 18.52 
PATNUM*REFNUM 0.94 3.42 0 0.10 56.08 
PATNUM*DNA% 0.02 0.10 0 0 1.89 
      
Performance      
REV 0.22 0.49 0.00 0.07 7.18 
MAR 0.07 0.46 -2.08 -0.02 6.71 
Obs = 1183 (872 for BETA)         
 
 
RETURN   = Change in market value of a firm in year t divided by market value of the firm at 
the end of year t-1. 
1/MVt-1  = Inverse of the market value of a firm at the end of year t-1.  
∆BVt   = Change in book value of a firm in year t. 
∆Et   = Change in earnings before R&D expenditures of a firm in year t. 
BVt-1   = Book value at the end of year t-1. 
Et-1   = Earnings before R&D expenditures at the end of year t-1. 
R&D   = R&D expenditures. 
PATNUM     = Number of U.S. patents granted to the company during a given year. 
PATNUM*CLAIM   = PATNUM and CLAIM interaction.  
PATNUM*CITATION = PATNUM and CITATION interaction. 
PATNUM*REFAGE = PATNUM and REFAGE interaction. 
PATNUM*REFNUM = PATNUM and REFNUM interaction. 
PATNUM*DNA%  = PATNUM and DNA% interaction. 
REV  = Sales revenue. 
MAR  = Margins, defined as sales revenue minus R&D expenses. 
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TABLE 2 CORRELATION MATRIX 
 
VARIABLES 
1/ 
MVt-1 
∆BVt/
MVt-1
∆Et/
MVt-1
BVt-1/
MVt-1
Et-1/
MVt-1
R&D/
MVt-1
PATNUM/ 
MVt-1 
 
CLAIM CITATION
∆BVt/MVt-1 -0.03 1        
 (0.32)    
∆Et/MVt-1 0.12 0.09 1    
 (0.00) (0.01)    
BVt-1/MVt-1 0.38 -0.10 0.15 1    
 (0.00) (0.00) (0.00)    
Et-1/MVt-1 -0.13 0.00 -0.70 0.00 1    
 (0.00) (0.97) (0.00) (0.98)    
R&D/MVt-1 0.21 0.13 0.07 0.69 0.14 1    
 (0.00) (0.00) (0.04) (0.00) (0.00)    
PATNUM/MVt-1 0.24 -0.02 0.11 0.16 -0.11 0.11 1   
 (0.00) (0.54) (0.00) (0.00) (0.00) (0.00)    
CLAIM -0.10 -0.04 -0.03 -0.08 -0.00 0.01 0.08 1  
 (0.00) (0.30) (0.39) (0.02) (0.93) (0.74) (0.01)   
CITATION -0.1 0.04 -0.01 -0.04 0.00 -0.05 -0.01 0.25 1
 (0.00) (0.30) (0.67) (0.28) (0.89) (0.11) (0.83) (0.00)  
REFAGE -0.12 -0.04 -0.02 -0.10 -0.01 -0.07 0.11 0.52 0.25
 (0.00) (0.24) (0.61) (0.00) (0.66) (0.05) (0.00) (0.00) (0.00)
REFNUM -0.12 0.01 -0.01 -0.09 0.02 -0.02 0.05 0.40 0.27
 (0.00) (0.81) (0.79) (0.01) (0.49) (0.62) (0.16) (0.00) (0.00)
DNA% -0.11 0.1 -0.02 -0.04 0.08 0.03 0.16 0.29 0.19
 (0.00) (0.00) (0.54) (0.28) (0.02) (0.36) (0.00) (0.00) (0.00)
REV/MVt-1 0.49 0.15 0.46 0.57 -0.20 0.40 0.16 -0.12 -0.08
 (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.01)
MAR/MVt-1 0.40 0.08 0.45 0.19 -0.30 -0.18 0.10 -0.14 -0.06
 (0.00) (0.02) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.09)
ROS 0.02 -0.09 0.03 0.05 0.04 -0.01 0.02 0.04 0.02
 (0.53) (0.01) (0.42) (0.13) (0.23) (0.83) (0.63) (0.24) (0.57)
BM 0.17 -0.06 0.22 0.57 -0.12 0.25 0.07 -0.13 -0.05
 (0.00) (0.08) (0.00) (0.00) (0.00) (0.00) (0.04) (0.00) (0.17)
MV -0.06 0.03 -0.01 -0.08 0.04 -0.06 -0.05 0.03 -0.02
 (0.06) (0.43) (0.83) (0.01) (0.24) (0.07) (0.17) (0.38) (0.60)
BETA -0.12 0.08 0.05 0.05 -0.00 0.14 -0.11 -0.01 0.12
 (0.00) (0.02) (0.16) (0.15) (0.95) (0.00) (0.00) (0.76) (0.00)
LnAsset -0.39 0.22 -0.03 -0.01 0.18 -0.01 -0.18 0.14 0.12
  (0.00) (0.00) (0.43) (0.73) (0.00) (0.80) (0.00) (0.00) (0.00)
 
Correlations greater than 0.40 are in bold, and probability > |r| under H0: Rho = 0 is in parenthesis. 
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TABLE 2 CONTINUED 
 
VARIABLES 
 
REFAGE REFNUM DNA%
REV/
MVt-1
MAR/
MVt-1 ROS BM MV BETA
REFAGE 1         
          
REFNUM 0.41 1        
 (0.00)         
DNA% 0.17 0.32 1       
 (0.00) (0.00)        
REV/MVt-1 -0.13 -0.11 -0.05 1  
 (0.00) (0.00) (0.17)  
MAR/MVt-1 -0.1 -0.11 -0.07 0.83 1  
 (0.00) (0.00) (0.04) (0.00)  
ROS 0.06 0.03 0.04 0.09 0.11 1  
 (0.08) (0.45) (0.23) (0.01) (0.00)  
BM -0.09 -0.07 -0.07 0.35 0.23 0.04 1 
 (0.01) (0.03) (0.05) (0.00) (0.00) (0.22)  
MV 0.05 0.10 0.13 -0.04 -0.003 0.03 -0.09 1
 (0.11) (0.00) (0.00) (0.27) (0.92) (0.42) (0.01) 
BETA -0.03 0.07 0.08 -0.07 -0.17 0.04 0.01 -0.07 1
 (0.40) (0.03) (0.01) (0.03) (0.00) (0.23) (0.67) (0.03)
LnAsset 0.15 0.24 0.33 -0.06 -0.06 0.06 0.01 0.41 0.11
  (0.00) (0.00) (0.00) (0.08) (0.08) (0.09) (0.86) (0.00) (0.00)
 
Correlations greater than 0.40 are in bold, and probability > |r| under H0: Rho = 0 is in parenthesis. 
Variable definitions appear in Table 1. 
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TABLE 3 DESCRIPTIVE STATISTICS OF UNDEFLATED VARIABLES AND SIC 
COMPOSITION FOR FIRMS WITH AND WITHOUT PATENTS 
 
Panel A: Undeflated Variables 
 
The full sample is partitioned by whether the firms have patents.  The top row of each variable is for firms 
with patents, and the bottom (in parenthesis) is for those without patents.   
 
Variable  Mean   Std Dev Min Median Max 
RETURN 0.60 * 2.64 -0.97 -0.08 40.25 
 (0.39)  (1.62) (-1.00) (-0.15) (9.60) 
      
Financial      
MVt-1 1045.90  6351.70 0.85 146.47 87878.60 
 (724.81)  (8211.88) (0.45) (67.09) (152398) 
R&D 36.10 *** 83.680 0 14.58 875.10 
 (11.87)  (24.98) (0) (5.27) (283.07) 
    
Patent      
PATNUM 6.94 *** 15.14 1 3 248 
 (0)  (0) (0) (0) (0) 
CLAIM 19.55 *** 13.85 0 16.83 176 
 (0)  (0) (0) (0) (0) 
CITATION 1.06 *** 1.89 0 0.59 30.61 
 (0)  (0) (0) (0) (0) 
REFAGE 6.56 *** 3.65 0 6.22 27.08 
 (0)  (0) (0) (0) (0) 
REFNUM 24.14 *** 24.92 0 17 230 
 (0)  (0) (0) (0) (0) 
DNA% 0.39 *** 0.40 0 0.29 1 
 (0)  (0) (0) (0) (0) 
      
Performance      
REV 71.71 *** 312.23 0.01 9.45 4015.70 
 (26.75)  (92.49) (0.01) (4.46) (981.93) 
MAR 35.61 ** 242.98 -654.64 -3.71 3150.70 
 (14.88)  (77.22) (-125.08) (-0.69) (698.86) 
ROS -6.52 ** 30.62 -482.95 -0.51 1 
 (-15.01)  (74.29) (-1000.37) (-0.25) (1) 
Obs = 799 (384)            
  
 
The notations *, **, and *** indicate that the mean of the variable for firms with patents is significantly 
different than that for firms without patents at the 10%, 5%, and 1% level, respectively. 
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TABLE 3 CONTINUED  
 
The full sample is partitioned by whether the firms have patents.  The top row of each variable is for firms 
with patents, and the bottom (in parenthesis) is for those without patents.   
 
Variable  Mean   Std Dev Min Median Max 
     
BM 0.34 *** 0.40 0.00 0.23 5.69 
 (0.44)  (0.56) (0) (0.29) (5.80) 
MV 1188.12 * 6285 1.04 179.85 87878.60 
 (606.97)  (5252.40) (0.34) (63.30) (87847.50)
BETA 1.69  0.74 0.03 1.65 5.06 
 (1.65)  (0.99) (0.003) (1.49) (6.44) 
LnASSET 4.02 *** 1.50 -0.06 3.92 8.77 
 (3.13)  (1.45) (-0.92) (3.22) (8.08) 
Obs = 799 (384)      
Obs = 612 (260) for BETA           
Control 
 
The notations * and *** indicate that the mean of the variable for firms with patents is significantly 
different than that for firms without patents at the 10% and 1% level, respectively. 
 
 
 
 
 
 
 
Panel B: SIC Composition 
 
 
 
 
 
 28
 2
 28
 87
 2
 
3
3
 O
 35
 
 
Without 
Patent
With 
Patent
with-patent 
obs as a % 
of subtotal
36 Biological products, except diagnostic substances 149 326 475 40.15 68.63
834 Pharmaceutical preparations 53 176 229 19.36 76.86
35 In vitro and in vivo diagnostic substances 84 136 220 18.60 61.82
31 Commercial physical and biological research 20 28 48 4.06 58.33
833 Medicinal chemicals and botanical products 7 24 31 2.62 77.42
841 Surgical and medical instruments and apparatus 11 14 25 2.11 56.00
842 Orthopedic, prosthetic, and surgical appliances and supplies 7 13 20 1.69 65.00
50 85 135 11.41 62.96
381 802 1183 100.00 67.79
Subtotal
(no. of obs. & %)
SIC Composition
thers (0100, 2810, 2820, 2821, 2840, 2860, 2844, 2870, 2890, 3559,
80, 3826, 3845, 3829, 7370, 5160, 6552, 6794, 7372, 8071, 9995)
Total
Firm-Year Obs
 
Other SICs list the SICs with less than 1% of the total sample observations (12 firm-year observations).   
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TABLE 4 REGRESSION OF RETURNS ON FINANCIAL, PATENT AND CONTROL 
VARIABLES 
 
RETURNjt = β0+ YR + ∑ FIRM + β∑
=
+
2001
1990
1
yr
yrβ
=
+
292
1
1
n
nβ 1 (1/ MVjt-1) + β2 ∆BVjt/ MVjt-1 + β3 BVjt-1/ MVjt-1 
 + β4 ∆Ejt/ MVjt-1 + β5 Ejt-1/ MVjt-1+ β6 R&Djt/ MVjt-1+ β7 PATNUMjt/ MVjt-1 + β8 (PATNUM*CLAIMjt)/ MVjt-1 
 + β9 (PATNUM*CITATIONjt)/ MVjt-1 + β10(PATNUM*REFAGEjt)/MVjt-1 + β11 (PATNUM*REFNUMjt)/ MVjt-1 
  + β12 (PATNUM*DNA%jt)/ MVjt-1 + β13 B/Mjt + β14 MVjt + β15 βjt + εjt .     (4) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Variables Mean
A B C
Constant -0.08 -0.12 -0.22
(-0.25) (-0.40) (-0.73)
1/MVt-1 3.86 ** 3.73 ** 4.19 **
(2.28) (2.18) (2.49)
∆BVt/MVt-1 1.57 *** 1.57 *** 1.54 ***
(7.63) (7.66) (7.48)
∆Et/MVt-1 0.34 0.33 0.96 **
(0.7) (0.67) (1.96)
BVt-1/MVt-1 2.41 *** 2.35 *** 2.05 ***
(7.44) (7.21) (6.4)
Et-1/MVt-1 -0.55 -0.42 0.40
(-0.98) (-0.76) (0.71)
R&D/MVt-1 -0.72 * -0.73 * -0.86 **
(-1.66) (-1.68) (-2.01)
PATNUM/MVt-1 1.27 ** -8.45 *** 0.05
(2.44) (-3.69)
(PATNUM*CLAIM)/MVt-1 0.33 *** 0.9
(5.00)
(PATNUM*CITATION)/MVt-1 5.07 *** 0.03
(3.62)
(PATNUM*REFAGE)/MVt-1 0.38 ** 0.31
(1.99)
(PATNUM*REFNUM)/MVt-1 0.00 1.06
(-0.08)
(PATNUM*DNA%)/MVt-1 1.64 0.02
(0.77)
BM -1.74 *** -1.72 *** -1.49 ***
(-8.63) (-8.54) (-7.45)
MV 0.00 0.00 0.00
(-0.28) (-0.17) (-0.07)
BETA 0.13 0.14 0.14
(1.18) (1.24) (1.29)
R2 0.23 0.23 0.29
Hausman test 7.86 11.73 11.7
F stat. for overall model 28.03 *** 25.74 *** 22.59 ***
9.08 ***
Obs 860 860 860
Coefficients
F stat. for joint significance of patent variables
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t-statistics are in the parenthesis.  The notations *, **, and *** refer to significance at the 10%, 5% and 1% 
levels.   
TABLE 4 CONTINUTED 
 
RETURNjt = β0+ YR + ∑ FIRM + β∑
=
+
2001
1990
1
yr
yrβ
=
+
292
1
1
n
nβ 1 (1/ MVjt-1) + β2 ∆BVjt/ MVjt-1 + β3 BVjt-1/ MVjt-1 
 + β4 ∆Ejt/ MVjt-1 + β5 Ejt-1/ MVjt-1+ β6 R&Djt/ MVjt-1+ β7 PATNUMjt/ MVjt-1 + β8 (PATNUM*CLAIMjt)/ MVjt-1 
 + β9 (PATNUM*CITATIONjt)/ MVjt-1 + β10(PATNUM*REFAGEjt)/MVjt-1 + β11 (PATNUM*REFNUMjt)/ MVjt-1 
  + β12 (PATNUM*DNA%jt)/ MVjt-1 + β13 B/Mjt + β14 MVjt + β15 βjt + εjt .     (4) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variables
D E F G H
Constant -0.19 -0.16 -0.12 -0.11 -0.11
(-0.63) (-0.55) (-0.40) (-0.37) (-0.35)
1/MVt-1 3.81 ** 3.58 ** 3.68 ** 3.93 ** 4.04 **
(2.25) (2.13) (2.16) (2.3) (2.36)
∆BVt/MVt-1 1.63 *** 1.43 *** 1.57 *** 1.56 *** 1.56 ***
(8.06) (6.98) (7.7) (7.64) (7.63)
∆Et/MVt-1 0.52 0.48 0.36 0.27 0.30
(1.07) (0.98) (0.74) (0.54) (0.61)
BVt-1/MVt-1 2.23 *** 2.26 *** 2.31 *** 2.40 *** 2.38 ***
(6.9) (6.98) (7.07) (7.39) (7.31)
Et-1/MVt-1 -0.06 -0.23 -0.36 -0.58 -0.54
(-0.10) (-0.41) (-0.64) (-1.04) (-0.96)
R&D/MVt-1 -0.86 ** -0.66 -0.70 -0.75 * -0.73 *
(-2.00) (-1.54) (-1.62) (-1.73) (-1.67)
(PATNUM*CLAIM)/MVt-1 0.15 ***
(5.05)
(PATNUM*CITATION)/MVt-1 4.28 ***
(4.22)
(PATNUM*REFAGE)/MVt-1 0.22 ***
(2.97)
(PATNUM*REFNUM)/MVt-1 0.05 **
(2.11)
(PATNUM*DNA%)/MVt-1 1.52 **
(2.08)
BM -1.62 *** -1.67 *** -1.71 *** -1.75 *** -1.74 ***
(-8.12) (-8.34) (-8.52) (-8.69) (-8.61)
MV 0.00 0.00 0.00 0.00 0.00
(-0.08) (-0.14) (-0.18) (-0.18) (-0.17)
BETA 0.15 0.13 0.14 0.14 0.13
(1.38) (1.14) (1.27) (1.21) (1.2)
R2 0.25 0.25 0.23 0.23 0.23
Hausman test 14.11 10.06 11.36 11.51 12.6
F stat. for overall model 28.36 *** 27.96 *** 26.00 *** 25.65 *** 25.55 ***
Obs 860 860 860 860 860
Coefficients
t-statistics are in the parenthesis.  The notations *, **, and *** refer to significance at the 10%, 5% and 1% 
levels.   
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TABLE 5 REGRESSION OF PERFORMANCE VARIABLES ON PATENT AND 
CONTROLVARIABLES 
 
PERFORMjt+n/MVjt-1 = γ0+ γ1 PATNUMjt/MVjt-1+ γ2 (PATNUM*CLAIMjt)/MVjt-1 
 + γ3 (PATNUM*CITATIONjt)/MVjt-1 + γ4 (PATNUM*REFAGEjt)/MVjt-1  
 + γ5 (PATNUM*REFNUMjt)/MVjt-1 + γ6 (PATNUM*DNA%jt)/MVjt-1  
 + γ7 PERFOMjt/ MVjt-1+ γ8 R&Djt/ MVjt-1 + γ9 LnASSETjt+n + ε jt+n,   n=1,2,…5. 
 (5.1), (5.2), &(5.3) 
Panel A: n = 1 
 
Variables
Dependent Variable
REVt+1/
MVt-1
MARt+1/
MVt-1 ROSt+1
Constant -0.04 0.07 -6.63 **
(-1.50) (0.95) (-2.00)
PATNUM/MVt-1 -0.99 -0.09 -12.28
(-0.93) (-0.14) (-0.43)
(PATNUM*CLAIM)/MVt-1 -0.01 0.04 * -2.29 **
(-0.91) (1.85) (-2.28)
(PATNUM*CITATION)/MVt-1 -0.07 -0.26 -7.11
(-0.41) (-.60) (-0.36)
(PATNUM*REFAGE)/MVt-1 0.02 -0.07 -1.84
(0.69) (-1.09) (-0.65)
(PATNUM*REFNUM)/MVt-1 -0.001 0.03 3.66 ***
(-0.22) (1.61) (4.90)
(PATNUM*DNA%)/MVt-1 0.29 -0.88 -63.71 **
(1.23) (-1.41) (-2.26)
REVt/MVt-1 1.06 ***
(46.58)
MARt/MVt-1 1.23 ***
(20.47)
ROSt 0.2 ***
(7.04)
R&D/MVt-1 0.56 *** -0.87 *** -0.8
(16.11) (-9.59) (-0.21)
LNASSET 0.002 -0.01 0.63
(0.27) (0.71) (0.80)
Adj. R2 0.79 0.42 0.09
F stat. for overall model 385.53 *** 77.00 *** 11.17 ***
F-stat. for joint 
significance of patent variables 1.56 1.32 8.04 ***
Obs 944 944 944
Coefficients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
t-statistics are in the parenthesis.  The notations *, **, and *** refer to significance at the 10%, 5%, and 1% 
levels.   
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TABLE 5 CONTINUED 
 
PERFORMjt+n/MVjt-1 = γ0+ γ1 PATNUMjt/MVjt-1+ γ2 (PATNUM*CLAIMjt)/MVjt-1 
 + γ3 (PATNUM*CITATIONjt)/MVjt-1 + γ4 (PATNUM*REFAGEjt)/MVjt-1  
 + γ5 (PATNUM*REFNUMjt)/MVjt-1 + γ6 (PATNUM*DNA%jt)/MVjt-1  
 + γ7 PERFOMjt/ MVjt-1+ γ8 R&Djt/ MVjt-1 + γ9 LnASSETjt+n + ε jt+n,   n=1,2,…5. 
 (5.1), (5.2), &(5.3) 
Panel B: n = 2 
 
 Variables
Dependent Variable
REVt+2/
MVt-1
MARt+2/
MVt-1 ROSt+2
Constant -0.13 *** 0.05 -4.08
(-2.48) (0.80) (-1.11)
PATNUM/MVt-1 -0.67 0.08 26.66
(-1.49) (0.15) (0.84)
(PATNUM*CLAIM)/MVt-1 -0.02 -0.001 -1.12
(-1.03) (-0.05) (-1.07)
(PATNUM*CITATION)/MVt-1 0.18 -0.003 10.66
(0.60) (-0.01) (0.51)
(PATNUM*REFAGE)/MVt-1 0.04 -0.21 *** -6.33 *
(0.82) (-3.75) (-1.81)
(PATNUM*REFNUM)/MVt-1 -0.01 0.07 *** 1.84 **
(-0.70) (5.27) (2.30)
(PATNUM*DNA%)/MVt-1 0.79 * -2.29 *** -76.3 **
(1.69) (-4.30) (-2.30)
REVt/MVt-1 1.29 ***
(31.83)
MARt/MVt-1 1.41 ***
(30.58)
ROSt 0.42 ***
(10.87)
R&D/MVt-1 1.19 *** 0.35 *** 1.15
(18.96) (5.16) (0.28)
LNASSET 0.01 -0.01 0.21
(0.78) (-1.00) (0.24)
Adj. R2 0.75 0.58 0.15
F stat. for overall model 247.61 *** 116.75 *** 15.5 ***
F-stat. for joint 
significance of patent variables 2.41 *** 19.23 *** 3.86 ***
Obs 757 757 757
Coefficients
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
t-statistics are in the parenthesis.  The notations *, **, and *** refer to significance at the 10%, 5%, and 1% 
levels.   
 63
TABLE 6 REGRESSION OF RETURNS ON FINANCIAL, PATENT AND CONTROL 
VARIABLES 
 
RETURNjt = β0+ YR + FIRM + β∑
=
+
2001
1990
1
yr
yrβ ∑
=
+
292
1
1
n
nβ 1 (1/ MVjt-1) + β2 ∆BVjt/ MVjt-1 + β3 BVjt-1/ MVjt-1 
 + β4 ∆Ejt/ MVjt-1 + β5 Ejt-1/ MVjt-1+ β6 R&Djt/ MVjt-1+ β7 PATNUMjt/ MVjt-1 + β8 CLAIMjt  
 + β9 CITATIONjt + β10 REFAGEjt + β11 REFNUMjt + β12 DNA%jt + β13 (PATNUM*CLAIMjt)/ MVjt-1 
 + β14 (PAT*CITATIONjt)/ MVjt-1 + β15 (PATNUM*REFAGEjt)/MVjt-1 + β16 (PATNUM*REFNUMjt)/ MVjt-1  
 + β17 (PATNUM*DNA%jt)/ MVjt-1 + β18 B/Mjt + β19 MVjt + β20 BETAjt + εjt  . (4’) 
 Variables Mean
A B C
Constant -0.08 -0.24 -0.09
(-0.25) (-0.76) (-0.29)
1/MVt-1 3.86 ** 4.15 ** 4.02 **
(2.28) (2.39) (2.37)
∆BVt/MVt-1 1.57 *** 1.55 *** 1.49 ***
(7.63) (7.51) (7.27)
∆Et/MVt-1 0.34 0.32 1.04 **
(0.7) (0.65) (2.12)
BVt-1/MVt-1 2.41 *** 2.34 *** 1.98 ***
(7.44) (7.15) (6.19)
Et-1/MVt-1 -0.55 -0.44 0.51
(-0.98) (-0.79) (0.89)
R&D/MVt-1 -0.72 * -0.73 * -0.87 **
(-1.66) (-1.67) (-2.04)
PATNUM/MVt-1 1.08 ** -9.66 *** 0.05
(2.03) (-4.07)
CLAIM 0.002 -0.02 *** 13.91
(0.34) (-2.95)
CITATION 0.01 -0.09 0.68
(0.17) (-1.19)
REFAGE 0.01 0.02 4.70
(0.24) (0.9)
REFNUM -0.003 -0.004 17.52
(-0.69) (-0.90)
DNA% 0.48 * 0.64 ** 0.28
(1.86) (2.41)
(PATNUM*CLAIM)/MVt-1 0.44 *** 0.90
(5.73)
(PATNUM*CITATION)/MVt-1 5.75 *** 0.03
(3.61)
(PATNUM*REFAGE)/MVt-1 0.35 * 0.31
(1.73)
(PATNUM*REFNUM)/MVt-1 0.05 1.05
(0.83)
(PATNUM*DNA%)/MVt-1 -0.79 0.02
(-0.34)
Coefficients
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
t-statistics are in the parenthesis.  The notations *, **, and *** refer to significance at the 10%, 5%, and 1% 
levels.   
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TABLE 6 CONTINUED 
RETURNjt = β0+ YR + FIRM + β∑
=
+
2001
1990
1
yr
yrβ ∑
=
+
292
1
1
n
nβ 1 (1/ MVjt-1) + β2 ∆BVjt/ MVjt-1 + β3 BVjt-1/ MVjt-1 
 + β4 ∆Ejt/ MVjt-1 + β5 Ejt-1/ MVjt-1+ β6 R&Djt/ MVjt-1+ β7 PATNUMjt/ MVjt-1 + β8 CLAIMjt  
 + β9 CITATIONjt + β10 REFAGEjt + β11 REFNUMjt + β12 DNA%jt + β13 (PATNUM*CLAIMjt)/ MVjt-1 
 + β14 (PAT*CITATIONjt)/ MVjt-1 + β15 (PATNUM*REFAGEjt)/MVjt-1 + β16 (PATNUM*REFNUMjt)/ MVjt-1  
+ β17 (PATNUM*DNA%jt)/ MVjt-1 + β18 B/Mjt + β19 MVjt + β20 BETAjt + εjt  . (4’) 
 
 Variables Mean
A B C
BM -1.74 *** -1.70 *** -1.49 ***
(-8.63) (-8.40) (-7.50)
MV 0.00 0.00 0.00
(-0.28) (-0.21) (-0.08)
BETA 0.13 0.12 0.14
(1.18) (1.07) (1.34)
R2 0.23 0.24 0.30
Hausman test 7.86 15.52 13.81
F stat. for overall model 28.03 *** 17.39 *** 18.24 ***
F stat. for joint significance 
of patent variables 2.97 *** 6.41 ***
Obs 860 860 860
Coefficients
 
 
 
 
 
 
 
 
 
 
 
 
 
 
t-statistics are in the parenthesis.  The notations *, **, and *** refer to significance at the 10%, 5%, and 1% 
levels.   
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TABLE 6 CONTINUED 
  
RETURNjt = β0+ YR + FIRM + β∑
=
+
2001
1990
1
yr
yrβ ∑
=
+
292
1
1
n
nβ 1 (1/ MVjt-1) + β2 ∆BVjt/ MVjt-1 + β3 BVjt-1/ MVjt-1 
 + β4 ∆Ejt/ MVjt-1 + β5 Ejt-1/ MVjt-1+ β6 R&Djt/ MVjt-1+ β7 PATNUMjt/ MVjt-1 + β8 CLAIMjt  
 + β9 CITATIONjt + β10 REFAGEjt + β11 REFNUMjt + β12 DNA%jt + β13 (PATNUM*CLAIMjt)/ MVjt-1 
 + β14 (PAT*CITATIONjt)/ MVjt-1 + β15 (PATNUM*REFAGEjt)/MVjt-1 + β16 (PATNUM*REFNUMjt)/ MVjt-1  
+ β17 (PATNUM*DNA%jt)/ MVjt-1 + β18 B/Mjt + β19 MVjt + β20 BETAjt + εjt  . (4’) 
 
Variables
D E F
Constant -0.12 -0.24 -0.20
(-0.40) (-0.74) (-0.65)
1/MVt-1 4.15 ** 4.17 ** 4.12 **
(2.4) (2.41) (2.38)
∆BVt/MVt-1 1.55 *** 1.54 *** 1.54 ***
(7.53) (7.53) (7.51)
∆Et/MVt-1 0.31 0.31 0.31
(0.64) (0.63) (0.64)
BVt-1/MVt-1 2.35 *** 2.35 *** 2.34 ***
(7.18) (7.17) (7.15)
Et-1/MVt-1 -0.45 -0.45 -0.46
(-0.80) (-0.81) (-0.81)
R&D/MVt-1 -0.74 * -0.73 * -0.72 *
(-1.70) (-1.68) (-1.65)
PATNUM/MVt-1 1.08 ** 1.08 ** 1.10 **
(2.05) (2.04) (2.09)
CLAIM 0.002
0.32
CITATION 0.01 0.01 0.02
(0.1) (0.12) (0.25)
REFAGE 0.004
(0.2)
REFNUM -0.002
(-0.55)
DNA% 0.45 * 0.47 * 0.5 **
(1.77) (1.87) (1.97)
BM -1.70 *** -1.70 *** -1.70 ***
(-8.42) (-8.45) (-8.46)
MV 0.00 0.00 0.00
(-0.25) (-0.26) (-0.21)
BETA 0.12 0.11 0.12
(1.02) (1.01) (1.04)
R2 0.24 0.24 0.24
Hausman test 15.49 15.51 15.46
F stat. for overall model 20.03 *** 19.99 *** 20.04 ***
of patent variables 4.37 *** 4.43 *** 4.38 ***
Obs 860 860 860
Coefficients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
t-statistics are in the parenthesis.  The notations *, **, and *** refer to significance at the 10%, 5%, and 1% 
levels.   
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TABLE 7 REGRESSION OF RETURNS ON FINANCIAL, PATENT AND CONTROL 
VARIABLES IN A SUBSAMPLE OF FIRMS WITH LOSSES BEFORE R&D 
EXPENDITURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variables Mean
A B C
Constant -1.03 * -1.20 ** -0.79
(-1.71) (-2.16) (-1.39)
1/MVt-1 32.73 *** 30.19 *** 25.98 ***
(4.41) (4.43) (3.87)
∆BVt/MVt-1 1.52 *** 1.57 *** 1.53 ***
(4.34) (4.46) (4.43)
∆Et/MVt-1 0.59 0.90 1.31
(0.43) (0.71) (1.06)
BVt-1/MVt-1 2.69 *** 1.19 1.23
(3.19) (1.4) (1.48)
Et-1/MVt-1 0.43 0.62 0.84
0.26 (0.35) (0.49)
R&D/MVt-1 -3.65 *** -4.82 *** -4.26 ***
(-2.99) (-4.13) (-3.66)
PATNUM/MVt-1 -38.25 *** -32.36 *** 0.05
(-5.28) (-5.35)
CLAIM -0.06 *** 13.60
(-3.63)
CITATION 0.05 0.67
(0.26)
REFAGE 0.04 4.72
(0.87)
REFNUM -0.02 ** 16.02
(-2.09)
DNA% 0.93 ** 0.22
(1.42)
(PATNUM*CLAIM)/MVt-1 0.36 *** 0.81 *** 0.94
(2.98) (4.65)
(PATNUM*CITATION)/MVt-1 8.36 *** 8.82 *** 0.04
(3.21) (3.00)
(PATNUM*REFAGE)/MVt-1 3.70 *** 3.07 *** 0.31
(4.58) (3.46)
(PATNUM*REFNUM)/MVt-1 0.31 *** 0.46 *** 0.91
(2.53) (3.35)
(PATNUM*DNA%)/MVt-1 3.62  -5.24 0.02
(0.62) (-0.83)
Coefficients
 
t-statistics are in the parenthesis.  The notations *, **, and *** refer to significance at the 10%, 5%, and 1% 
levels.   
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TABLE 7 CONTINUED 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variables Mean
A B C
BM -1.29 *** -0.53 -0.53
(-2.88) (-1.26) (-1.30)
MV 0.00 * 0.00 ** 0.00 **
(1.69) (2.15) (1.94)
BETA 0.28 0.44 0.6 **
(0.94) (1.6) (2.19)
Adj. R2 0.30 0.43 0.47
Hausman test 21.54 ** 32.46 *** 29.82 *
F stat. for overall model 2.22 *** 3.09 *** 3.32 ***
F stat. for joint significance 
of patent variables 11.00 *** 8.31 ***
Obs 391 391 391
Coefficients
 
t-statistics are in the parenthesis.  The notations *, **, and *** refer to significance at the 10%, 5%, and 1% 
levels.   
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